Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281479466> ?p ?o ?g. }
- W4281479466 abstract "Immunotherapy with immune checkpoint inhibitor (ICI) drugs is gradually becoming a hot topic in cancer treatment. To comprehensively evaluate the safety and efficacy of ICI drugs, we employed the Bayesian model and conducted a network meta-analysis in terms of progression-free survival (PFS), overall survival (OS) and severe adverse events (AEs). Our study found that treatment with ipilimumab was significantly worse than standard therapies in terms of PFS, whereas treatment with cemiplimab significantly improved PFS. The results also indicated that cemiplimab was the best choice for PFS. Treatment with nivolumab, pembrolizumab and nivolumab plus ipilimumab significantly improved OS compared to standard therapies. In terms of OS, cemiplimab was found to be the best choice, whereas avelumab was the worst. In terms of severe AEs, atezolizumab, avelumab, durvalumab, nivolumab, and pembrolizumab all significantly reduced the risk of grade 3 or higher AEs compared to standard therapy. The least likely to be associated with severe AEs were as follows: cemiplimab, avelumab, nivolumab, atezolizumab, and camrelizumab, with nivolumab plus ipilimumab to be the worst. Therefore, different ICI drug therapies may pose different risks in terms of PFS, OS and severe AEs. Our study may provide new insights and strategies for the clinical practice of ICI drugs." @default.
- W4281479466 created "2022-05-26" @default.
- W4281479466 creator A5001082939 @default.
- W4281479466 creator A5011943498 @default.
- W4281479466 creator A5017541508 @default.
- W4281479466 creator A5018863416 @default.
- W4281479466 creator A5050987382 @default.
- W4281479466 creator A5052042524 @default.
- W4281479466 creator A5061536548 @default.
- W4281479466 creator A5064108264 @default.
- W4281479466 creator A5072817423 @default.
- W4281479466 creator A5075448668 @default.
- W4281479466 creator A5084566885 @default.
- W4281479466 date "2022-05-25" @default.
- W4281479466 modified "2023-09-22" @default.
- W4281479466 title "Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis" @default.
- W4281479466 cites W1617328014 @default.
- W4281479466 cites W1987273470 @default.
- W4281479466 cites W1992699637 @default.
- W4281479466 cites W2097995306 @default.
- W4281479466 cites W2104347254 @default.
- W4281479466 cites W2119388029 @default.
- W4281479466 cites W2126930838 @default.
- W4281479466 cites W2136746908 @default.
- W4281479466 cites W2156353875 @default.
- W4281479466 cites W2160834915 @default.
- W4281479466 cites W2161817962 @default.
- W4281479466 cites W2198093519 @default.
- W4281479466 cites W2222086386 @default.
- W4281479466 cites W2293531514 @default.
- W4281479466 cites W2519279652 @default.
- W4281479466 cites W2529484692 @default.
- W4281479466 cites W2560367415 @default.
- W4281479466 cites W2572174216 @default.
- W4281479466 cites W2635951006 @default.
- W4281479466 cites W2725487442 @default.
- W4281479466 cites W2726861941 @default.
- W4281479466 cites W2752227448 @default.
- W4281479466 cites W2766729634 @default.
- W4281479466 cites W2767421465 @default.
- W4281479466 cites W2777192533 @default.
- W4281479466 cites W2794577178 @default.
- W4281479466 cites W2803847828 @default.
- W4281479466 cites W2805302875 @default.
- W4281479466 cites W2806614796 @default.
- W4281479466 cites W2883552436 @default.
- W4281479466 cites W2893602866 @default.
- W4281479466 cites W2894584497 @default.
- W4281479466 cites W2896600825 @default.
- W4281479466 cites W2898510820 @default.
- W4281479466 cites W2898717093 @default.
- W4281479466 cites W2900174742 @default.
- W4281479466 cites W2903493423 @default.
- W4281479466 cites W2908684819 @default.
- W4281479466 cites W2908914600 @default.
- W4281479466 cites W2909198142 @default.
- W4281479466 cites W2910245285 @default.
- W4281479466 cites W2925446385 @default.
- W4281479466 cites W2938645074 @default.
- W4281479466 cites W2943108118 @default.
- W4281479466 cites W2959096163 @default.
- W4281479466 cites W2963476376 @default.
- W4281479466 cites W2969242120 @default.
- W4281479466 cites W2976652879 @default.
- W4281479466 cites W2976744492 @default.
- W4281479466 cites W2977339506 @default.
- W4281479466 cites W2997351648 @default.
- W4281479466 cites W3008027480 @default.
- W4281479466 cites W3015755028 @default.
- W4281479466 cites W3016085372 @default.
- W4281479466 cites W3016210953 @default.
- W4281479466 cites W3024460671 @default.
- W4281479466 cites W3025003676 @default.
- W4281479466 cites W3026551532 @default.
- W4281479466 cites W3042095160 @default.
- W4281479466 cites W3081958456 @default.
- W4281479466 cites W3082736986 @default.
- W4281479466 cites W3087466624 @default.
- W4281479466 cites W3090469545 @default.
- W4281479466 cites W3091399767 @default.
- W4281479466 cites W3092384992 @default.
- W4281479466 cites W3110528877 @default.
- W4281479466 cites W3121740707 @default.
- W4281479466 cites W3122627530 @default.
- W4281479466 cites W3127182916 @default.
- W4281479466 cites W3129022890 @default.
- W4281479466 cites W3133896744 @default.
- W4281479466 cites W3135755572 @default.
- W4281479466 cites W3137610925 @default.
- W4281479466 cites W3155244800 @default.
- W4281479466 cites W3164197656 @default.
- W4281479466 cites W3169849224 @default.
- W4281479466 cites W3194098004 @default.
- W4281479466 doi "https://doi.org/10.3389/fphar.2022.883655" @default.
- W4281479466 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35694260" @default.
- W4281479466 hasPublicationYear "2022" @default.
- W4281479466 type Work @default.
- W4281479466 citedByCount "7" @default.
- W4281479466 countsByYear W42814794662022 @default.
- W4281479466 countsByYear W42814794662023 @default.